A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Lin Gui,1 Shaoyan Liu,2 Ye Zhang,3 Yuankai Shi1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Mol...

Full description

Bibliographic Details
Main Authors: Gui L, Liu S, Zhang Y, Shi Y
Format: Article
Language:English
Published: Dove Medical Press 2021-04-01
Series:OncoTargets and Therapy
Subjects:
anaplastic thyroid carcinoma
pd-1 inhibitor
anti-angiogenesis drug
tert promoter mutations
tp53 mutations
nras mutation
next generation sequencing.
Online Access:https://www.dovepress.com/a-remarkable-and-durable-response-to-sintilimab-and-anlotinib-in-the-f-peer-reviewed-fulltext-article-OTT

Internet

https://www.dovepress.com/a-remarkable-and-durable-response-to-sintilimab-and-anlotinib-in-the-f-peer-reviewed-fulltext-article-OTT

Similar Items